Association of Vitamin D level with Disease Activity in SLE patients at a Tertiary Care Hospital
A BEGUMa, MT MIAHb, KFM AYAZc, MSS SHANCHAYd, J DASE

Abstract:
Introduction: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with increased prevalence in recent years. One of the extra skeletal functions of vitamin D is involved in regulation of immune response. Objectives: This study was to determine vitamin D status in SLE patients and the relationship with disease activity.

Methods: This prospective observational study was conducted at Medicine department in Dhaka Medical College and Hospital. Data regarding disease activity of SLE was taken from 50 SLE patients fulfilling ACR criteria and disease activity was calculated by SLEDAI score. Vitamin D level was quantified by ELISA.

Results: Out of 50 patients, 46(92%) were female and 4(8%) were male. Age range was 15 to 65 years and mean age was 28.00 ± 13.34 SD. Most of the population reside in rural areas (n=32, 64%) and rest from urban areas (n=18, 36%). Common presentations were fever (62%), proteinuria (50%), rash (40%), vasculitis (36%) and hematuria (34%). Overall mean SLEDAI score was 18.24 ± 9.67. Among the study population, 21(42%) patients had very highly active disease, 12(24%) patients had highly active disease, 11(22%) patients had moderately active disease and 6(12%) patients had mildly active disease. Mean vitamin D level was 16.70 ± 8.83 ng/ml. In this study, majority were found to be vitamin D deficient 37(74%), out of rest 7(14%) patients had insufficient vitamin D level and 6(12%) patients had sufficient vitamin D. This study showed that there is negative linear correlation between SLEDAI score and vitamin D level which is statistically significant (p value <0.001 and r=-0.577).

Conclusion: Low vitamin D level in SLE patients correlated with increased disease activity.

Keywords: (Systemic Lupus Erythematosus) SLE, SLE Disease Activity Index (SLEDAI), Vitamin D (Vit D).

(J Bangladesh Coll Phys Surg 2022; 40: 105-110) DOI: https://doi.org/10.3329/jbcps.v40i2.58691

Introduction:
SLE is a chronic multisystem inflammatory autoimmune disease characterized by immunological abnormalities resulting in production of auto antibodies. This autoimmune-mediated inflammation are stimulated by uptake of nucleic acid containing immune complexes by plasmacytoid dendritic cells and the resulting activation of Type I interferon expression. This inflammatory milieu promotes defective function of regulatory T cells (Tregs) and hyperactivity of helper T cells (Th cells), and the survival and activation of auto reactive B cells that produce autoantibodies1. Evidence suggests that vitamin D impacts negatively on many of these events. This includes vitamin D-induced down regulation of the Th1 immune response and of the proliferation of activated B cells2 while up regulating Tregs3. A recent study showed that vitamin D3 inhibits dendritic cell maturation and expression of IFN-á induced genes in SLE patients4. Vitamin D deficiency is highly prevalent in patients with SLE because of factors such as avoidance of sunshine due to photosensitivity5, the use of sun-screen6, chronic renal insufficiency7 and the use of medications such as glucocorticoids8. Very few studies regarding level of vitamin D in patients with SLE has yet been conducted in Bangladesh. Therefore the data generated from the present study might be helpful to determine the level of vitamin D and to observe its association with disease activity in SLE patients.
Materials and Methods:

Design of the Study

A prospective observational study was conducted at Medicine indoor of Dhaka Medical College Hospital. After getting approval from Dhaka Medical Ethical Review Committee, this study was done for six months of period, September 2016 to February, 2017 and patients suffering from SLE presenting to DMCH were recruited to participate in the study. Total 50 cases were enrolled and convenient sampling technique was used. All the SLE patients (based on ACR criteria) with or without getting treatment and who gave informed written consent were included in the study. Patients who have received vitamin D supplementation within previous 3 months were excluded. SLE patients with Chronic Kidney Disease, Chronic Liver Disease, Gastro-intestinal and Exfoliative skin disease were also excluded. A Pretested Structured Questionnaire Form was filled accordingly.

After a detailed clinical examination and lab investigation, the clinical manifestations were categorized according to SLE Disease Activity Index (SLEDAI). It is a scoring system by which disease severity of SLE can be measured.

Mild activity (SLEDAI = 1-5)
Moderate activity (SLEDAI = 6-10)
High activity (SLEDAI = 11-19)
Very high activity (SLEDAI >20)

Vitamin D (25(OH)D3) level was assessed using ELISA technique and categorized into 3 different levels:

Deficiency- 20 ng/ml or less
Insufficiency- 21 to 29 ng/ml
Sufficient - 30 ng/ml or more

Statistical Analysis

After editing and coding, the coded data directly entered into the computer by using SPSS 22 for WINDOWS RELEASE version. Data cleaning validation and analysis was performed using the SPSS/PC software. Graph and chart are by MS excel. Correlation between SLEDAI score and vitamin D level was analyzed by Pearson’s Correlation test. Statistical significance was defined as p-value < 0.05.

Results:

Mean age was 28.00 ±13.34 with ranging from 15 to 65 years. 27 patients (54%) were of 15-24 years, 11 patients (22%) were 25-34 years, 8 patients (16%) were 45-54 years and 2 patients (4%) were from each of group 35-44 years and 65-74 years [figure 1]. There were 92% female SLE patients and 8% male SLE patients in this study [figure 2]. Among 50 cases majority came from rural area (32, 64%) and rest of patients were staying at urban area (18, 36%) (Figure 3). Most common presentation was fever (62%), followed by Increased DNA binding as determined by Farr assay (54%), proteinuria (50%), rash (40%), vasculitis (36%) and hematuria (34%) (Table I).
Mean Vitamin D level was also higher in female (17.12±8.94) than that of male (11.80±6.35). There was no significant difference in distribution. Mean Vitamin D level was also higher in female (17.12±8.94) than male 11.80±6.35, but the distribution across group was not significant either (Table II). In this study, 42% SLE patients had very highly active disease, 24% patients had highly active disease, 22% patients had moderately active disease and 12% patients had mildly active disease (figure 4). Majority were found to be vitamin D deficient (74%). 14% patients had insufficient vitamin D level and 12% patients were deficient in Vitamin D (figure 5). Pearson’s correlation co-efficient revealed a significant negative linear correlation between SLEDAI and vitamin D level. This means that SLEDAI decreased with increased vitamin D level in the blood (Figure 6).

### Table-I

| Clinical manifestations of SLE patients (n=50) | Frequency | Percentage |
|----------------------------------------------|-----------|------------|
| Seizure                                      | 2         | 4%         |
| Visual disturbance                           | 3         | 6%         |
| Lupus Headache                               | 10        | 20%        |
| Vasculitis                                   | 18        | 36%        |
| Arthritis                                    | 4         | 8%         |
| Urinary Casts                                | 5         | 10%        |
| Hematuria                                    | 17        | 34%        |
| Proteinuria                                  | 25        | 50%        |
| Pyuria                                       | 9         | 18%        |
| Rash                                         | 20        | 40%        |
| Alopecia                                     | 11        | 22%        |
| Mucosal Ulcers                               | 8         | 16%        |
| Pleurisy                                     | 6         | 12%        |
| Pericarditis                                 | 2         | 4%         |
| Low Complement                               | 26        | 52%        |
| Increased DNA binding                        | 27        | 54%        |
| Fever                                        | 31        | 62%        |
| Thrombocytopenia                             | 7         | 14%        |
| Leukopenia                                   | 2         | 4%         |

Overall mean SLEDAI score was 18.24±9.67 and mean Vitamin D level was 16.70±8.83 SD ng/ml. Mean SLEDAI was higher in female (17.12±8.94) than that of male (11.80±6.35). There was no significant difference in distribution. Mean Vitamin D level was also higher in female (17.12±8.94) than male 11.80±6.35, but the distribution across group was not significant either (Table II). In this study, 42% SLE patients had very highly active disease, 24% patients had highly active disease, 22% patients had moderately active disease and 12% patients had mildly active disease (figure 4). Majority were found to be vitamin D deficient (74%). 14% patients had insufficient vitamin D level and 12% patients were deficient in Vitamin D (figure 5). Pearson’s correlation co-efficient revealed a significant negative linear correlation between SLEDAI and vitamin D level. This means that SLEDAI decreased with increased vitamin D level in the blood (Figure 6).

### Table-II

| Mean, Standard deviation, maximum and minimum SLEDAI and vitamin D level (n=50) |
|-----------------------------------------------------------------------------|
| Minimum | Maximum | Mean  | Std. Deviation | P value* |
|---------|---------|-------|----------------|----------|
| SLEDAI  | Female (n=46) | 4     | 34             | 17.12   | 8.94   | 0.213 |
|         | Male (n=4)   | 23    | 26             | 11.80   | 6.35   |
|         | Total (n=50) | 4     | 34             | 18.24   | 9.67   |
| Vitamin D(ng/ml) | Female(n=46) | 1.80 | 34.30 | 17.12 | 8.94 | 0.213 |
|         | Male (n=4)   | 6.30  | 17.30 | 11.80 | 6.35  |
|         | Total (n=50) | 1.8   | 34.3 | 16.70 | 8.84 |
Discussion:
A total 50 SLE patients were studied and among the study population female are more prevalent. There were 92% female and 8% male. SLE is more common in females, where the reported female: male ratio is 8–15:1. The findings of this study is also supported by study done by Mandal M et al. and Nightingale Al et al.[13,14]. Mean age was 28.00 ±13.34 with ranging 15 to 65 years. SLE is a disease that can affect persons of all ages and ethnic groups and both sexes, but more than 90% of new patients presenting with SLE are women in the childbearing years. Similar mean age (28.14 ± 8.43 SD) was found in a study by Mandal M et al [14]. Though slight difference (Mean age 31.12±11.2 SD years) was found in study done by Handono K et al [16]. This difference could be the effect of different health seeking behavior pattern in different geographical variations.

In this study, most common presentation was fever (62%), followed by increased DNA binding as determined by Farr assay (54%), proteinuria (50%), rash (40%), vasculitis (36%) and hematuria (34%). In study of Bertsias G et al. shows common pattern of clinical manifestation were photosensitivity rash(26%), malar rash (57%), discoid rash (11%), oral ulcer (59%), arthritis (60%), neuropsychiatric disease (9%), myocarditis (2%), serositis (5%), nephritis (37%) and vasculitis (13%). Arthritis was more common with advancing age (93% vs 72%, p<0.001), whereas renal disease (44% vs 33%, p=0.001), alopecia (47% vs 23%, p<0.001) and aphthous ulcerations (39% vs 26%, p=0.001) were more common in the young. Neuropsychiatric lupus was less common in mature-onset SLE (p<0.01). SLE was associated more commonly with thrombocytopenia (21% vs 15%, p=0.01), haemolytic anaemia (20% vs 3%, p<0.001). Leucopenia increased with advancing age (p<0.001). This study showed mean Vitamin D level was 16.70 ng/ml. Mean Vit-D level was also higher in female (17.12±8.94) than male 11.80± 6.35, but the distribution across group was not statistically significant (p value 0.213>0.05).This findings slightly lower the study done by Kalim H et al. He revealed that the mean of serum vitamin D level in his study was 22.80 ± 16.23 ng/m.
he could not examine the effect of sex difference with vitamin D level\textsuperscript{18}.

In this study, majority were found to be vitamin D deficient (74%). 14% patients had insufficient vitamin D level and 12% patients were deficient in Vitamin. The findings is dissimilar with the study of Handono K et al. evidenced 55.56% with deficiency of vitamin D, 24.7% with insufficiency and 20.37% of SLE patients had normal vitamin D serum level \cite{16}. Another study done by Kalim H et al. showed deficiency, insufficiency and normal level of vitamin D among SLE patients were 25.5%, 61.8% and 14.7% respectively\textsuperscript{18}. This findings showed that low vitamin D level was frequent in SLE patients, and indicated that SLE patients had higher risk of insufficiency of vitamin D\textsuperscript{19}. The high prevalence of SLE patients who have vitamin D level below normal was similar with other studies, with percentage between 50-75%, however those studies were performed in different latitude and ethnicity\textsuperscript{20-22}.

According to the SLEDAI score, 42% SLE patients had very highly active disease, 24% patients had highly active disease, 22% patients had moderately active disease and 12% patients had mildly active disease. Overall, mean SLEDAI score of all study population was 18.24±9.67 SD. Mean SLEDAI was higher in female (17.12±8.94 SD) than male (11.80±6.35 SD). There was no significant difference of SLEDAI score among female and male (p value .213>.05). Moreover, Pearson’s correlation co-efficient revealed a significant negative linear correlation between SLEDAI and vitamin D level. This means that SLEDAI decreased with increased vitamin D level in the blood and vice versa. Similar correlation is found in the study Handono K et al. \cite{21} (p<.0000, r = -.659) and Mandal M et al. \cite{13} (P <0.0001, r = “0.42). A study performed by Sung in Korea showed that vitamin D did not correlate with disease activity\textsuperscript{21}.

**Conclusion:**
The mean vitamin D in SLE patients studied was low. The significant inverse relationship was found between serum vitamin D level and disease activity scores in SLE studied population. It indicates necessity for vitamin D supplementation in the management of SLE patients.

**Conflict of Interest:** All the authors do not have any conflict of interest in the subject matter or materials discussed in the manuscript.

**References:**
1. Liu Z, Davidson A. Taming lupus—a new understanding of pathogenesis is leading to clinical advances. Nat Med 2012;18:871–82.
2. Lemire JM, Adams JS, Sakai R, et al. 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 1984;74:657–61.
3. Boonstra A, Barrat FJ, Crain C, et al. 1 alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4\textsuperscript{+} T cells to enhance the development of Th2 cells. J Immunol 2001;167:4974–80.
4. Ben-Zvi I, Aranow C, Mackay M, et al. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS One 2010;5:e9193.
5. Ruiz-Irastorza G, Egurdebe MV, Olivares N, Martinez-Berriotxoa A, Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. J Rheumatology (Oxford) 2008; 47(6): 920-923.
6. Cusack C, Danby C, Fallon JC, et al. Photo protective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photo dermatol Photo immunol Photomed 2008;24:260–7.
7. Sumethkul K, Boonyaratavej S, Kitumnuayoung T, et al. The predictive factors of low serum 25-hydroxyvitamin D and vitamin D deficiency in patients with systemic lupus erythematosus. RheumatolInt 2012;33:1461–7.
8. Akeno N, Matsunuma A, Maeda T, et al. Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney. J Endocrinol 2000;164:339–48.
9. Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. ClinExpRheumatol 2006; 24 (Suppl. 43): S100-S104.
10. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006;81:353-73.
11. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. OsteoporosInt 2005;16:713-6.
12. Lu LJ, Wallace DJ, Ishimori ML, et al. Male systemic lupus erythematosus: a review of sex disparities in this disease, Lupus 2010;19:119-29.
13. Nightingale AL, Davidson JE, Molta CT, et al. Presentation of SLE in UK primary care using the Clinical Practice Research Datalink. Lupus Science & Medicine 2017;4:e00172.
14. Mandal M, Tripathy R, Panda AK, Pattanaik SS, Dukua S, Pradhan AK et al. Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index,and interferon alpha. Arthritis Research & Therapy 2014; 16:1-8.

109
15. Shirai H, Shoda H, Kobayashi S, Fujio K, Setoguchi K & Yamamoto K. Two cases of very elderly onset male lupus patient; the characteristics and sex differences of elderly onset systemic lupus erythematosus patients Case Report. Journal of Modern Rheumatology Case Reports. 2017:1-5

16. Handono K, Puspitasari L, Rudijanto A, Wahono S, Kalim H. Vitamin D Serum Level And Disease Activity In Patients With Systemic Lupus Erythematosus. International Journal of Pharmaceutical Science Invention 2013; 2(2):35-40.

17. Bertsias G, Cervera R, Boumpas DT. Systemic Lupus Erythematosus: Pathogenesis and Clinical Features. Chapter 20. EULAR Textbook on Rheumatic Diseases. 476-506.

18. Kalim H, Wahono S, Suryana P, Puspitasari L, Wijayanto FH, Handono K. Association between serum level of Vitamin D with autoantibodies expression, disease activity (SLEDAI) and bone mineral density (BMD) in patients with Systemic Lupus Erythematosus (SLE). Arthritis Res Ther. 2012; 14(Suppl 1): P23.

19. Orbach H, Zandman-Goddard G, Amital H, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y AcadSci 2007; 1109:385–400.

20. Toloza S, Cole D, Glandman D, Ibanez D, Urowitz M. Vitamin D Insufficiency in Large Female SLE Cohort. Lupus, 19, 2010, 13-9.

21. Kim H-A, Sung J-M, Yoon J-M, Jeon J-Y, Suh C-H. Vitamin D may not be a Good Marker of Disease Activity in Korean Patients with Systemic Lupus Erythematosus. RheumatolInt, 2010.

22. Carvalho J, Blank M, Kiss E, Tarr T, Amital H, Shoenfeld Y. Anti-Vitamin D, Vitamin D in SLE. Ann N Y AcadSci [Preliminary Result], 1109, 2007, 550-7.